Merck Entered into Clinical Trial Collaboration with Carisma to Evaluate Keytruda (pembrolizumab) + CAR-M for HER2 Positive Cancers
Shots:
- The companies collaborated to evaluate Carisma’s CAR-M + Merck’s Keytruda for HER2 overexpressing cancers patients. The study is expected to launch in 2022
- Carisma's CAR-M platform can reprogram the solid tumor microenvironment for immune activation, T cell recruitment & anti-tumor adaptive immunity, based on pre-clinical results
- In preliminary results, CT-0508 was well tolerated after infusion & no dose-limiting toxicities were observed, and showed high CAR expression while immunotherapy was successfully manufactured using macrophages from heavily pretreated, advanced solid tumor patients. Additionally, CT-0508 has received FTD from the US FDA for solid tumors
Ref: PR Newswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com